查詢結果分析
相關文獻
- Effects of Oral Propafenone in Patients with Frequent Ventricular Extrasystoles
- Multi-Undulant T-U-wave, Sinus Bradycardia and Long QT Syndrome: A Possible Phenotype of Mutant Genes Controlling the Inward Potassium Rectifiers
- 基於混合訊號處理的嵌入式霍特心電圖機設計
- Amiodarone for recurring ventricular arrhythmias--Assessment by 24-hour Holter Ambulatory Electrocardiography
- 霍特心電圖及其臨床應用
- 醫師涉嫌作出虛偽診斷書
頁籤選單縮合
題 名 | Effects of Oral Propafenone in Patients with Frequent Ventricular Extrasystoles=口服propafenone對頻發性心室期外收縮病人的效果 |
---|---|
作 者 | 曾春典; 林俊立; 江福田; 許寬立; 駱惠銘; 曾淵如; | 書刊名 | 慈濟醫學 |
卷 期 | 9:4 1997.12[民86.12] |
頁 次 | 頁259-264 |
分類號 | 418.22 |
關鍵詞 | 心室期外收縮; 霍特心電圖; propafenone; Propafenone; Ventricular ectopies; Holter monitoring; |
語 文 | 英文(English) |
中文摘要 | Propafenone是一種具有鈉離子通道阻斷、輕度乙型阻斷和鈣離子通道阻斷性質的 抗心律不整藥物。 口服 propafenone 已被證明對上心室性和心室性心律不整具有療效。然 而此藥在中國人的經驗則未曾被報告。 為探討口服 propafenone 對有頻發性心室期外縮及 正常運動試驗及超音波心圖中國人的治療效果與安全性,吾等針對 23 位(其中男性 14 位 , 女性 9 位,平均年齡 56.5 歲)經由霍特心電圖記錄證實有 >20 次 / 小時心室期外收 縮的病人給予 propafenone 治療,其中 12 位 300 mg/day,另外 11 位 450 mg/day。 服 藥四週後再重覆霍特心電圖記錄以比較 propafenone 對心室期外收縮的抑制效果。 並於每 週門診時測量血壓並詢問有無副作用。 結果發現接受 300mg/day 者對心室期外收縮沒有明 顯的抑制效果,而接受 450mg/day 者對心室期外收縮有明顯的抑制效果。 在治療成功(壓 制 85% 以上的心室期外收縮)的比率方面,接受 300 mg/day 者為 5 位( 41.7% ), 而 接受 450mg/day 者為 7 位( 63.6% )。接受 450 mg/day 者失敗的 3 位中,有兩位在增 加劑量到 600mg/day 後可成功地壓制 85% 以上的心室期外收縮; 副作用方面雖然有 3 位 的霍特心電圖呈現一過度心搏過緩,但均無不適之主訴或血行力學不穩之現象。因此我們結 論為口服 propafenone 300-600 mg/day 對心臟機能正常併頻發性心室期外收縮的病人為有 效且安全的治療方式。 |
英文摘要 | Propafenone is an antiarrhythmic drug with class IC sodium channel blocking agent with mildly β -blocking and calcium channel blocking properties. Oral therapy effectively suppresses supraventricular and ventricular arrhythmias. However, experience with propafenone in Chinese patients is limited. To assess the efficacy and safety of oral propafenone in Chinese patients with frequent ventricular extrasystoles (>20/hour in average) and normal treadmill exercise test and echocardiographic results, 23 patients (14 males and 9 females, mean age 56.5 years) were studied using 24-hour Holter ECG recording. Oral propafenone at a dose of 300 mg/day (12 patients) and 450 mg/day (11 patients) was then given. The 24-hour Holter ECG recording was repeated 4 weeks later to evaluate the suppressive effect of propafenone. Blood pressure and adverse effects were also recorded at each visit. When all patients taking 300 mg/day were analyzed as a group, no stastistically significant suppresion of ventricular extrasystoles was noted, whereas patients taking 450 mg/day had significant suppression of total ventricular ectopies, isolated ventricular ectopies, and average ventricular ectopies. Therapeutic success (>85% suppression of ventricular ectop) was achieved in 41.7% (5/12) of in those taking 300 mg/day and in 63.6% (7/11) of those taking 450 mg/day. Of the three patients taking 450 mg/day, who did not achieve >85% suppression, two patients showed significant suppression of ventricular ectopies without adverse effects when the dose was increased to 600 mg/day. During the treatment period, no patient reported arrhythmia-related ill effects or developed hemodynamic instability, although three patients had transient and asymptomatic bradycardia during the 24-hour Holter ECG recording. Therefore, we conclude that oral propafenone is effective at a dose range of 300 to 600 mg/day is effective and safe in the suppression of frequent ventricular extrasystoles in patients with functionally normal heart. |
本系統中英文摘要資訊取自各篇刊載內容。